pd 169316 has been researched along with Injury, Myocardial Reperfusion in 1 studies
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwertz, H | 1 |
| Carter, JM | 1 |
| Abdudureheman, M | 1 |
| Russ, M | 1 |
| Buerke, U | 1 |
| Schlitt, A | 1 |
| Müller-Werdan, U | 1 |
| Prondzinsky, R | 1 |
| Werdan, K | 1 |
| Buerke, M | 1 |
1 other study available for pd 169316 and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor.
Topics: Animals; Antibodies, Phospho-Specific; Cardiotonic Agents; Electrophoresis, Gel, Two-Dimensional; He | 2007 |